Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announces the renewal of its strategic cooperation agreement with Fudan University Shanghai Cancer Center (hereinafter referred to as “FUSCC”). Dr. Liu Datao , Chairman of the Board and CEO of Mabwell, and Prof. Yu Xianjun (President of FUSCC) attended the signing ceremony and signed the strategic cooperation agreement. 

Leveraging the scientific and technological innovation capabilities of Mabwell and the academic advantages of FUSCC, both parties will continue to engage in in-depth cooperation in scientific research, talent cultivation, hospital management, and platform construction. FUSCC will provide scientific considerations for clinical research to early-stage R&D strategies on new targets and support the high-quality conduct of clinical studies of Mabwell. In addition, both parties will also establish a talent exchange and cooperative training platform, formulate targeted talent training and further education plans, conduct domestic and international talent exchange training, and build a scientific research platform to enhance the research capabilities of FUSCC. 

Currently, Mabwell has several clinical studies rapidly advancing at FUSCC, and plans to further strengthen cooperation in the key development areas such as antibody-drug conjugates (ADCs) and tumor immunotherapy. Both parties will continue to jointly promote research in clinical oncology and translational medicine, contributing to the innovative development of the pharmaceutical industry and accelerating benefits to cancer patients in China.